{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:10:17Z","timestamp":1761808217070,"version":"3.40.5"},"reference-count":13,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bulcan.2018.08.014","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T20:00:02Z","timestamp":1541188802000},"page":"1147-1156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u00c9valuation de la disparit\u00e9 de prise en charge des patients avec une leuc\u00e9mie lympho\u00efde chronique en France"],"prefix":"10.1016","volume":"105","author":[{"given":"Yann","family":"Rateau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6649-9666","authenticated-orcid":false,"given":"Michael","family":"Harbouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-9992","authenticated-orcid":false,"given":"Xavier","family":"Troussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2008","series-title":"Estimation nationale de l\u2019incidence et de la mortalit\u00e9 par cancer en France entre 1980\u00a0et 2005","author":"Belot","key":"10.1016\/j.bulcan.2018.08.014_bib0070"},{"key":"10.1016\/j.bulcan.2018.08.014_bib0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2018.08.014_bib0080","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2018.08.014_bib0085","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938\u00a0previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2018.08.014_bib0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8\u00a0trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2018.08.014_bib0095","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2018.08.014_bib0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2018.08.014_bib0105","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.08.014_bib0110","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/jech-2011-200311","article-title":"Construction of an adaptable European transnational ecological deprivation index: the French version","volume":"66","author":"Pornet","year":"2012","journal-title":"J Epidemiol Community Health"},{"issue":"4","key":"10.1016\/j.bulcan.2018.08.014_bib0115","first-page":"68","article-title":"Environnement socio\u00e9conomique et incidence des cancers en France","author":"Bryere","year":"2017","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.bulcan.2018.08.014_bib0120","unstructured":"L\u2019\u00e9tat de la population en France. Rapport 2017\u00a0Drees. [Rapport r\u00e9alis\u00e9 sous la direction de : Nathalie Fourcade et Franck von Lennep (DREES), Isabelle Gr\u00e9my et Fran\u00e7ois Bourdillon (Sant\u00e9 publique France) et sous la coordination scientifique de : Lorenza Luciano et Sylvie Rey (DREES) Emmanuelle Bauchet, Isabelle Gr\u00e9my et Michel Vernay (Sant\u00e9 publique France)]."},{"year":"2018","series-title":"\u00ab\u00a010\u00a0000\u00a0m\u00e9decins de plus depuis 2012\u00a0\u00bb. \u00c9tudes et R\u00e9sultats","author":"Anguis","key":"10.1016\/j.bulcan.2018.08.014_bib0125"},{"key":"10.1016\/j.bulcan.2018.08.014_bib0065","unstructured":"Atlas de la d\u00e9mographie m\u00e9dicale en France\u00a0: situation au 1er janvier 2016. Conseil national de l\u2019Ordre des m\u00e9decins Dr Patrick Bouet, Pr\u00e9sident Sous la direction du Dr Jean-Fran\u00e7ois Rault, Pr\u00e9sident de la Section Sant\u00e9 Publique et D\u00e9mographie M\u00e9dicale. R\u00e9alis\u00e9 par Gw\u00e9na\u00eblle Le Breton-Lerouvillois, G\u00e9ographe de la sant\u00e9."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118302777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118302777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T10:14:45Z","timestamp":1572516885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118302777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0007455118302777"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.08.014","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9valuation de la disparit\u00e9 de prise en charge des patients avec une leuc\u00e9mie lympho\u00efde chronique en France","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}